Green Cross Hong Kong Holdings

Green Cross Hong Kong Holdings is a specialized holding company that manages the Chinese operations of the South Korean biopharmaceutical leader, GC Biopharma. Its primary asset is Anhui Green Cross Pharmaceutical, a major player in the Chinese plasma products market. The company's product portfolio includes essential blood-derived therapies such as human albumin, intravenous immunoglobulin, and coagulation factors used to treat hemophilia and immune disorders. In July 2024, CR Boya Bio-Pharmaceutical, a unit of China Resources, acquired the company for approximately $250 million to expand its footprint in the blood products sector. This acquisition marks a strategic shift in the ownership of one of the few foreign-invested plasma companies in China.